

Prevision Medicine Drug Screening Test for MM

Relevant Publications

2023 [Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma](#) KROPIVSEK ET AL NATURE CANCER

In a cohort of 70 Multiple Myeloma patients, ex vivo drug sensitivity screening with Pharmacoscopy significantly stratified clinical treatment responses to a wide range of MM treatments, including immunotherapies.

2021 [Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders*](#) KORNAUTH ET AL CANCER DISCOV

In patients with advanced hematological malignancies, Pharmacoscopy-guided therapy significantly improved progression-free survival, and identified highly effective treatments which achieved exceptional responses in 40% of responding patients.

2023 [Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options*](#) SCHMID ET AL HAEMATOLOGICA

This study confirms that Pharmacoscopy is a clinically feasible and effective tool for treatment-refractory AML, providing actionable therapeutic guidance leading to a three-fold increase in overall survival for patients who otherwise had no remaining standard treatment options.

*Only Kropivšek et al. (2023) directly evaluates Pharmacoscopy in multiple myeloma. Kornauth et al. (2021) and Schmid et al. (2023) demonstrate the clinical utility and efficacy of Pharmacoscopy in other hematologic malignancies and are included to provide evidence supporting the clinical performance of the technology underlying the Prevision Medicine Drug Screening Test.